Kyowa Hakko Kirin Co., Ltd. announced that top-line results of the Japanese Phase 3 trial of KHK7580 met its primary endpoint. This study to evaluate the efficacy and safety of KHK7580 orally administered once daily for 30 weeks in subjects with secondary hyperparathyroidism receiving hemodialysis in a randomized, double-blind, intra-subject dose-adjustment, parallel-group design study with cinacalcet hydrochloride (Product Name: REGPARA®), which was already approved in Japan, as an active control. The top-line results indicated the non-inferiority for efficacy and the significant reduction in the incidence of the upper gastrointestinal tract disorder of KHK7580 compared with the active control.